REVIVA PHARMA HLDGS INC
RVPH
RVPH was delisted on the 13th of May, 2026.
48 hedge funds and large institutions have $3.18M invested in REVIVA PHARMA HLDGS INC in 2025 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 12 increasing their positions, 8 reducing their positions, and 9 closing their positions.
642% more call options, than puts
Call options by funds: $1.83M | Put options by funds: $246K
67% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 9
50% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 8
14% more funds holding
Funds holding: 42 → 48 (+6)
0.19% less ownership
Funds ownership: 0.69% → 0.49% (-0.19%)
10% less capital invested
Capital invested by funds: $3.52M → $3.18M (-$337K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$709K |
| 2 |
Jane Street
New York
|
+$371K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$308K |
| 4 |
Millennium Management
New York
|
+$307K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$272K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DP
Diadema Partners
Morristown,
New Jersey
|
-$1.39M |
| 2 |
PAP
Persistent Asset Partners
Hong Kong
|
-$330K |
| 3 |
Renaissance Technologies
New York
|
-$79.8K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
-$63K |
| 5 |
Cetera Investment Advisers
Schaumburg,
Illinois
|
-$20.1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
51
Simplex Trading
Chicago,
Illinois
| – | -$63K | -8,626 | Closed |
|
|
SSA
52
Schonfeld Strategic Advisors
New York
| – | -$17.8K | -2,421 | Closed |
|
|
TRCT
53
Tower Research Capital (TRC)
New York
| – | -$8.26K | -1,121 | Closed |
|
54
SG Americas Securities
New York
| – | -$4K | -578 | Closed |
|
|
DWM
55
Drive Wealth Management
Lehi,
Utah
| – | -$3.69K | -500 | Closed |
|
|
IAS
56
Insigneo Advisory Services
Miami,
Florida
| – | -$3.69K | -500 | Closed |
|
RVPH Hedge Fund Activity: Q4 2025 in Review
48 of the 8,252 institutional investors tracked by Wall St. Rank reported a position in REVIVA PHARMA HLDGS INC (RVPH) for Q4 2025, worth a combined $3.18M — down 9.6% from $3.52M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new RVPH positions and 9 closed out — a net gain of 6 holders — while 12 added to existing stakes and 8 trimmed.
The largest buyer was Vanguard Group, adding an estimated $709K. The largest seller was Diadema Partners, exiting entirely with an estimated $1.39M sold.
- 48 institutional investors held REVIVA PHARMA HLDGS INC (RVPH) as of Q4 2025, up from 42 in Q3 2025.
- Funds reported $3.18M of REVIVA PHARMA HLDGS INC stock for Q4 2025, down 9.6% quarter-over-quarter.
- 15 funds opened new REVIVA PHARMA HLDGS INC positions in Q4 2025 and 9 closed out, a net change of +6 holders.
- The largest REVIVA PHARMA HLDGS INC buyer in Q4 2025 was Vanguard Group, an estimated $709K added.
- The largest REVIVA PHARMA HLDGS INC seller in Q4 2025 was Diadema Partners, an estimated $1.39M sold.
Based on aggregated 13F filings for Q4 2025.